Furthermore, multiple FDA-approved inhibitors of CDK4/6 are already used in clinical practice, and the good clinical tolerability profiles of these drugs make them prime candidates for use in combination therapy, as exemplified by their current use in combination with hormonal therapy in estrogen receptor–positive breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.